Ligand acquires portfolio of biologics and biosimilars from Selexis

12 May 2015

US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a portfolio of more than 15 biologic development programs from Swiss biotech company Selexis for a cash payment of $4 million.

The assets include a mix of novel biologics and biosimilars at various stages of development from preclinical to Phase III, with each program fully-funded by a development partner.

Ligand acquired a separate portfolio from Selexis in April 2013, and since then many programs have advanced through development, meaning Ligand has received milestone payments amounting to nearly 10% of the acquisition price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK